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Abstract
Fibrodysplasia ossificans progressiva (FOP) is a congenital disorder of progressive and widespread
postnatal ossification of soft tissues1–4 and is without known effective treatments. Affected
individuals harbor conserved mutations in the ACVR1 gene that are thought to cause constitutive
activation of the bone morphogenetic protein (BMP) type I receptor, activin receptor-like kinase-2
(ALK2)5. Here we show that intramuscular expression in the mouse of an inducible transgene
encoding constitutively active ALK2 (caALK2), resulting from a glutamine to aspartic acid change
at amino acid position 207, leads to ectopic endochondral bone formation, joint fusion and functional
impairment, thus phenocopying key aspects of human FOP. A selective inhibitor of BMP type I
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receptor kinases, LDN-193189 (ref. 6), inhibits activation of the BMP signaling effectors SMAD1,
SMAD5 and SMAD8 in tissues expressing caALK2 induced by adenovirus specifying Cre (Ad.Cre).
This treatment resulted in a reduction in ectopic ossification and functional impairment. In contrast
to localized induction of caALK2 by Ad.Cre (which entails inflammation), global postnatal
expression of caALK2 (induced without the use of Ad.Cre and thus without inflammation) does not
lead to ectopic ossification. However, if in this context an inflammatory stimulus was provided with
a control adenovirus, ectopic bone formation was induced. Like LDN-193189, corticosteroid
treatment inhibits ossification in Ad.Cre-injected mutant mice, suggesting caALK2 expression and
an inflammatory milieu are both required for the development of ectopic ossification in this model.
These results support the role of dysregulated ALK2 kinase activity in the pathogenesis of FOP and
suggest that small molecule inhibition of BMP type I receptor activity may be useful in treating FOP
and heterotopic ossification syndromes associated with excessive BMP signaling.
Individuals with FOP typically present within the first decade of life with progressive ectopic
calcification of muscles and connective tissues after physical trauma, surgery, viral illness or
myositis1–4. FOP results in severe debilitation and reduced life expectancy due to joint fusion
and restrictive lung disease with thoracic involvement. A recent linkage and sequencing
analysis identified heterozygous mutations in ACVR1, the gene encoding the BMP type I
receptor ALK2, in all affected members from seven families5,7. BMP ligands facilitate the
phosphorylation and activation of BMP type I receptors (ALK2, ALK3 and ALK6) by BMP
type II receptors (BMPRII, ActRIIA and ActRIIB). Activated BMP type I receptors
phosphorylate BMP-responsive SMAD1, SMAD5 and SMAD8, which translocate to the
nucleus to regulate the transcription of genes, including the Inhibitor of DNA binding (ID)
gene family, with broad effects on growth and differentiation8. The classic FOP-associated
ALK2 mutation, R206H, is predicted to disrupt an α-helix in the glycine-serine regulatory
domain and alter local electrostatic potential to perturb intra- or intermolecular interactions
required for kinase regulation5,9, rendering ALK2 constitutively active. Heterozygous
mutations affecting the adjacent residue, Q207E, have been identified in phenotypic variant
FOP10. The Q207E mutation and a well described man-made ALK2 mutation affecting the
same residue, Q207D11, may exert similarly disruptive effects on the glycine-serine domain
structure and to cause constitutive activation of ALK2. In vivo, transfer of the gene encoding
ALK2Q207D but not wild-type ALK2 induces chondrogenic differentiation in chick embryos
and promotes endochondral bone growth in cortical allografts12,13, consistent with potent
osteogenic effects of constitutively activating ALK2 mutations.
To further explore the ability of constitutively active ALK2 to induce ectopic calcification, we
took advantage of the availability of transgenic mice expressing an inducible ALK2Q207D
(CAG-Z-EGFP-caALK2, or conditional caALK2). When the transgene is globally expressed
during embryogenesis, mice are arrested at mid-gestation14, in contrast to individuals with
FOP, who appear essentially normal at birth except for shortened great toes2. To circumvent
the embryonic lethality of this transgene, we induced postnatal over-expression of
ALK2Q207D in the left hindlimbs of mice with retro-popliteal injection of Ad.Cre (1 × 108
plaque-forming units (PFU)) on postnatal day 7 (P7). High-frequency, Cre-mediated
recombination was evident by P11, with loss of nuclear β-galactosidase staining and gain of
cytoplasmic GFP expression in myocytes, ligaments and vasculature only in the injected area
(Fig. 1a). Mononuclear infiltrates and myofiber edema were apparent in the left gastrocnemius,
soleus and hamstring muscles, consistent with myositis induced by intramuscular adenovirus
injection15, whereas muscles of uninjected limbs appeared normal (Fig. 1a).
Conditional caALK2–expressing mice injected with Ad.Cre in the left hindlimb developed
severely decreased mobility in the injected limb by P30, with loss of passive flexion in hip,
knee and ankle joints when examined under anesthesia, whereas wild-type mice injected with
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Ad.Cre retained normal posture and range of motion (Fig. 1b). By radiography and micro-
computed tomography (μCT), bony calluses were evident in injected hindlimbs of conditional
caALK2–expressing mice, circumferentially encasing the tibia and fibula (Fig. 1b,c). These
calluses frequently fused with the pelvis and femur, rendering hip, knee and ankle joints
immobile and extended and preventing the use of those limbs during locomotion
(Supplementary Videos 1 and 2 online). At P30, the penetrance of heterotopic ossification and
immobility associated with local induction of caALK2 by this technique was 100% (data not
shown).
We recently identified a small-molecule inhibitor of BMP type I receptors, dorsomorphin (Fig.
2a), which selectively blocks ALK2, ALK3 and ALK6 activity16. We subsequently described
the synthesis of potent and specific derivatives of dorsomorphin6. By reiteratively testing
modifications of the parent molecule, we found that replacement of the pendent pyridine ring
with a 4-quinolinyl group could improve potency that replacement of the 2-(1-piperidinyl)
ethoxy group with piperazine improved metabolic stability and that, in general, modifications
of the pyrazolo[1,5-a]pyrimidine core were not tolerated6. An optimized molecule,
LDN-193189 (Fig. 2a), inhibited BMP4-mediated Smad1, Smad5 and Smad8 activation with
greater potency than did dorsomorphin (half-maximal inhibitory concentration (IC50) = 5 nM
versus 470 nM) while retaining 200-fold selectivity for BMP signaling versus transforming
growth factor-β (TGF-β) signaling (IC50 for TGF-β ≥ 1,000 nM; Fig. 2a–c). LDN-193189
efficiently inhibited transcriptional activity of the BMP type I receptors ALK2 and ALK3
(IC50 = 5 nM and 30 nM, respectively), with substantially weaker effects on activin and the
TGF-β type I receptors ALK4, ALK5 and ALK7 (IC50 ≥ 500 nM, Supplementary Fig. 1 online)
and increased selectivity for BMP signaling versus AMP-activated protein kinase, platelet-
derived growth factor receptor and mitogen–activated protein kinase signaling pathways as
compared to the parent compound16 (Supplementary Fig. 2 online). LDN-193189 blocked the
transcriptional activity induced by either constitutively active ALK2R206H or ALK2Q207D
mutant proteins (Fig. 2d,e). These findings suggest that LDN-193189 might affect BMP-
induced osteoblast differentiation. In fact, LDN-193189 inhibited the induction of alkaline
phosphatase activity in C2C12 cells by BMP4 even when administered 12 h after BMP
stimulation (Fig. 2f), indicating sustained BMP signaling activity is needed for osteogenic
differentiation, as we have previously observed in vascular smooth muscle cells17.
To assess the impact of ALK2Q207D on BMP signaling, we isolated and cultured pulmonary
artery smooth muscle cells (PASMCs) from conditional caALK2–expressing mice. Baseline
phosphorylation of Smad1, Smad5 and Smad8 was increased in cells infected with Ad.Cre
compared to those infected with Ad.GFP (Fig. 2g), consistent with increased basal BMP
signaling after Cre-mediated induction of ALK2Q207D. PASMCs expressing ALK2Q207D also
showed hyperresponsiveness to BMP ligands, consistent with observations in cells that express
the mutant ALK2R206H protein18,19. Enhanced Smad1, Smad5 and Smad8 activation in cells
expressing ALK2Q207D was effectively inhibited by treatment with LDN-193189 (Fig. 2g).
To determine the pharmacokinetics of LDN-193189, we measured its plasma concentration
after administration of a single dose (3 mg kg−1 intraperitoneally (i.p.)) in C57BL/6 mice.
LDN-193189 remained at levels several fold higher than its in vitro IC50 for >8 h
(Supplementary Fig. 3 online), suggesting sustained inhibition of BMP signaling might be
obtained by bolus dosing. To assess the effect of ALK2 kinase inhibition on ectopic
calcification in vivo, we injected conditional caALK2–transgenic and wild-type mice with
Ad.Cre on P7 and then treated them with LDN-193189 (3 mg kg−1 i.p. every 12 h) or with
vehicle. Ad.Cre injection of conditional caALK2–transgenic mice led to mild calcifications
surrounding the left tibia and fibula first visible at P13 on X-ray (Fig. 3a). By P15, these lesions
were more prominent and extended to involve the distal femur (Fig. 3a). Lesions that effectively
joined the hip, femur and tibia-fibula were present in all vehicle-treated, Ad.Cre-injected mice
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by P30, progressing to fusion of the left hip, knee and ankle joints by P60 (Fig. 3a and
Supplementary Fig. 4 online). Treatment of Ad.Cre-injected, caALK2-expressing mice with
LDN-193189 prevented radiographic lesions at P15 in all mice examined (Fig. 3a). At P30,
LDN-193189 prevented ectopic bone in approximately two-thirds of mice and attenuated
lesions in the remainder, whereas at P60 LDN-193189 prevented ectopic bone in one-third of
mice and attenuated lesions in the remainder (Supplementary Fig. 4). In contrast to vehicle-
treated mice, LDN-193189–treated mice appeared to preserve knee and ankle joints at P30 and
P60. Alizarin red and Alcian blue staining of vehicle-treated caALK2-expressing mice at P15
revealed ectopic bone encasing the tibia and fibula and increased cartilage formation in
surrounding tissues (Fig. 3b,c). LDN-193189-treated mice showed no ectopic bone at P15 but
did show enhanced cartilage formation in surrounding soft tissues compared to wild-type mice.
Vehicle-treated, caALK2-expressing mice developed extensive ossification and fusion by P30
on μCT, whereas LDN-193189-treated, caALK2-expressing mice had small ectopic
ossifications without joint fusion (Fig. 3d). Radiographic lesions in vehicle-treated mice
correlated with abnormal hindlimb posture and decreased passive range of motion of hip, knee
and ankle joints when the mice were examined under anesthesia, all of which were attenuated
in LDN-193189-treated mice (Fig. 3e). A quantitative measure of passive range of motion in
the ankle joint (Fig. 3f) appeared to be a sensitive marker of functional impairment (Fig. 3g),
correlating with severe lesions found in vehicle-treated mutant mice while demonstrating
significant rescue of function in LDN-193189–treated mice. In fact, LDN-193189–treated mice
showed at least mildly impaired range of motion even in the absence of radiographically visible
disease at P30, perhaps reflecting enhanced cartilage formation or early calcification (Fig. 3a–
c,g). Consistent with this functional end point, vehicle-treated mice progressively lost use of
the left hindlimb owing to joint fusion, whereas LDN-193189–treated mice retained use of the
left hindlimb during ambulation at P15 and P30 (Supplementary Videos 3–6 online). Treatment
of wild-type or mutant mice with LDN-193189 under this regimen did not cause weight loss
or growth retardation (Supplementary Fig. 5 online), spontaneous fractures, decreased bone
density (Fig. 3a) or lead to other skeletal, morphologic, hematological or behavioral
abnormalities (data not shown).
Vehicle-treated, Ad.Cre-injected, caALK2-expressing mice showed increased amounts and
nuclear accumulation of phosphorylated Smad1, Smad5 and Smad8 in the left gastrocnemius,
soleus and hamstring muscles (Fig. 4a), whereas the uninjected right gastrocnemius had little
detectable phosphorylated Smad1, Smad5 and Smad8. Consistent with enhanced Smad1,
Smad5 and Smad8 signaling, Id1 expression was more than threefold greater in the hindlimb
muscles of Ad.Cre-injected, caALK2-expressing mice than in wild-type or uninjected mutant
controls (Supplementary Fig. 6 online). Within Ad.Cre-injected muscle tissues, but not
controls, a subset of myocyte-like cells was observed to express the osteogenic runt-related
transcription factor-2 (Runx2; Fig. 4a). Treatment of conditional caALK2–transgenic mice
with LDN-193189 did not have an impact on recombination efficiency, myocyte edema or
inflammation, but did result in diminished phosphorylated Smad1, Smad5 and Smad8 and
Runx2 staining in the left gastrocnemius (Fig. 4a). By P15, maturing endochondral bone,
marked by alkaline phosphatase–positive osteoblasts, chondrocyte-like cells and marrow cells
were evident in Ad.Cre-injected muscles of conditional caALK2–expressing mice (Fig. 4b).
The hindlimbs of Ad.Cre-injected, conditional caALK2–expressing mice treated with
LDN-193189 developed substantially less endochondral bone but retained evidence of
inflammation and myocyte injury (Fig. 4b). Histological evolution of lesions in affected mice
thus paralleled that of human intramuscular FOP lesions, showing myocyte injury and
inflammatory infiltrate followed by elaboration of a chondrogenic matrix, osteoblast-mediated
mineralization and maturation into endochondral bone20. This process of ectopic ossification,
beginning with activation of Smad1, Smad5 and Smad8, was markedly attenuated by
LDN-193189 treatment.
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To test the sufficiency of transgenic expression of caALK2 for the development of ectopic
bone, we used an alternate recombination strategy. We achieved global postnatal expression
of ALK2Q207D by mating conditional caALK2–transgenic mice with CAGGS-CreER mice,
which express a tamoxifen-inducible Cre recombinase ubiquitously21. Double-transgenic mice
were injected with tamoxifen (0.5 mg i.p.) on P7, inducing high-frequency recombination of
the gene segment encoding CAG-Z-EGFP-caALK2 throughout hindlimb muscle and vascular
and connective tissues, as indicated by the loss of nuclear β-galactosidase staining (Fig. 4c).
Muscle tissues undergoing recombination by this technique did not show edema or
mononuclear cell infiltrates. In contrast to Ad.Cre-induced recombination, global postnatal
overexpression of ALK2Q207D did not lead to detectable radiological ossification by P60 (Fig.
4d). When double-transgenic mice were injected with tamoxifen on P7 and injected with a
control adenovirus (Ad.GFP, 1 × 108 PFU, left popliteal fossa) on P8, mildly decreased left
hindlimb range of motion and small ectopic calcifications appeared by P14 (Fig. 4e). These
data suggest that expression of caALK2 is by itself insufficient to produce ectopic bone, and
that inflammation or tissue injury from viral immunogenicity or cytotoxicity might be required
for bone formation. To test this hypothesis, we treated conditional caALK2–expressing mice
with dexamethasone (10 mg kg−1 d−1 i.p.) starting 1 d after Ad.Cre injection at P7 and assessed
them for ectopic calcification. By P30, ectopic calcifications and immobility were markedly
reduced in corticosteroid-treated mice compared with vehicle-treated mice (Fig. 4f,g). The
impact of corticosteroid treatment suggests that inflammation and caALK2 expression are both
required to form ectopic bone. Unlike LDN-193189 administration, dexamethasone
administration was accompanied by toxicity, reflected by severely impaired weight gain during
drug administration (Supplementary Figs. 5 and 7 online).
These studies provide a model of heterotropic ossification that recapitulates key features of
human FOP, including the evolution of intramuscular endochondral bone and radiological and
functional outcomes. Episodes of ectopic ossification in afflicted humans are frequently
precipitated by viral prodromes and accompanying viral myositis22. Formation of ectopic bone
in conditional caALK2–transgenic mice in conjunction with local adenovirus infection and the
response to corticosteroid treatment support a similar relationship between ossification and
inflammation in the mouse model as suggested in previous reports23,24. These studies confirm
the role of dysregulated ALK2 kinase activity in the molecular pathogenesis of FOP19 while
demonstrating the potential of rational therapy mediated through inhibition of ALK2. Despite
this promising result, it is worthwhile to note that before any human therapy can be considered
using this approach, comprehensive and long-term toxicity studies in multiple species and
further drug refinement and optimization will be necessary to ensure adequate safety of both
the compound and chronic or intermittent inhibition of BMP signaling in vivo. Moreover, the
ability of LDN-193189 to prevent ectopic ossification in conditional caALK2–transgenic mice
was incomplete. It is possible that LDN-193189, in the manner it was administered, was
insufficient to completely suppress activation of SMAD signaling. It is also conceivable that
activation of SMAD-independent pathways, which were not blocked by dorsomorphin (ref.
16) and may not be inhibited by LDN-193189, can contribute to the ectopic ossification
associated with caALK2 expression.
BMP signals have pivotal roles in vertebrate development, regulating gastrulation, patterning
and organogenesis by specifying the fate of multipotent cells25. In contrast, the postnatal roles
of BMP signals are most essential in the contexts of injury repair, inflammation or remodeling,
in the skeleton as well as in connective and vascular tissues26,27. Given the apparent
requirement for injury and enhanced BMP signaling for FOP lesions in humans and mice, it
is possible that abnormal ossification results from diversion of an injury repair program toward
bone formation, perhaps deviating the normal adaptive response of cells with regenerative
potential. Understanding the cellular basis of endochondral bone formation in FOP could yield
insights into the mechanism of heterotopic ossification of auto-immune, post-traumatic or
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postsurgical etiologies and reveal how BMPs specify plasticity of mesenchyme-derived tissues
in physiology and in disease.
METHODS
Chemical, protein and viral agents
We purchased dorsomorphin (Compound C, 6-[4-(2-piperidin-1-yl-ethoxy)phenyl]-3-
pyridin-4-yl-pyrazolo[1,5-a]pyrimidine) from EMD Biosciences. We synthesized
LDN-193189 (4-[6-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline) as
previously described6, determined its purity (99.8%) by HPLC and confirmed its structure
by 1H-NMR and high-resolution mass spectrometry. The vehicle was 2% (wt/vol) (2-
hydroxypropyl)-β-cyclodextrin in PBS, pH 7.4. We purchased dexamethasone from Sigma.
Recombinant human BMP4, platelet-derived growth factor-BB and TGF-β were obtained from
R&D Systems. We produced adenoviruses expressing GFP and Cre and quantified them by
the plaque-titer method.
Conditionally-expressed, constitutively-active ALK2–transgenic mice
The construction of mice expressing a single conditionally expressed allele of the gene
encoding constitutively-active ALK2Q207D (CAG-Z-EGFP-caALK2) on a C57BL/6
background was previously described14. We obtained CAGGS-CreER mice, which express a
tamoxifen-inducible Cre recombinase ubiquitously under the control of the cytomegalovirus
immediate-early enhancer and the chicken β-actin promoter/enhancer20, from the Jackson
Laboratory. All mouse experiments were approved by the Massachusetts General Hospital
Subcommittee on Research Animal Care.
Cell culture
We isolated PASMCs from wild-type and CAG-Z-EGFP-caALK2–transgenic mice as
previously described28 and cultured them in RPMI medium (Invitrogen) supplemented with
10% FBS. We induced recombination of PASMCs expressing conditional caALK2 in vitro by
infecting with Ad.Cre (multiplicity of infection of 50) or Ad.GFP as a control and then culturing
for 3 d and passaging. We cultured C2C12 myofibroblast cells (American Type Culture
Collection) in DMEM (Invitrogen) supplemented with glutamine and 10% FBS. We
preincubated cells with pharmacological inhibitors for 10 min and then exposed them to BMP4,
TGF-β or platelet-derived growth factor-BB ligands for 30 minutes at 37 °C.
Immunoblot analysis of Smad1, Smad5 and Smad8 phosphorylation
We mechanically homogenized cell extracts in SDS-lysis buffer (62.5 mM Tris-HCl (pH 6.8),
2% SDS, 10% glycerol, 50 mM dithiothreitol and 0.01% bromophenol blue), separated the
proteins by SDS-PAGE, immunoblotted with polyclonal antibodies specific for
phosphorylated Smad1, Smad5 and Smad8, phosphorylated Smad2 (Cell Signaling
Technology) or rabbit monoclonal antibodies specific for Smad1 (Epitomics) or Smad2 (Cell
Signaling), and visualized the immunoreactive proteins with ECL Plus (GE Healthcare).
Alkaline phosphatase activity
We seeded C2C12 cells into 96-well plates at 2,000 cells per well in DMEM supplemented
with 2% FBS. We treated the wells in quadruplicate with BMP ligands and LDN-193189 or
vehicle. We collected the cells after 6 d in culture in 50 μl Tris-buffered saline and 1% Triton
X-100. We added the lysates to p-nitro-phenylphosphate reagent in 96-well plates (Sigma) for
1 h and then evaluated alkaline phosphatase activity (absorbance at 405 nm). We measured
cell viability and quantity by Cell Titer Aqueous One (absorbance at 490 nm, Promega), using
replicate wells treated identically to those used for alkaline phosphatase measurements.
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Visualization of skeletal mineralization
We fixed soft tissues and bone and stained them with Alizarin red and Alcian blue as previously
described29.
Radiography
For plain film radiography, we anesthetized the mice with ketamine and xylazine and then
immobilized them and X-rayed them. For three-dimensional images, we killed the mice and
analyzed them with a desktop microtomographic imaging system (μCT40, Scanco Medical
AG) equipped with a 10-mm focal spot microfocus X-ray tube. We acquired transverse CT
slices of the lower pelvis and hindlimbs with a 12-μm isotropic voxel size. We reconstructed,
filtered and thresholded the images with a specimen-specific threshold.
Histology
We killed mice and fixed their limbs in 0.5% paraformaldehyde in PBS overnight and then
decalcified them in 14% EDTA disodium salt solution with daily changes for 3 d. We incubated
the limbs overnight in 30% sucrose with PBS, embedded them in optimal cutting-temperature
medium and prepared 12-μm sections with the Cryo-Jane system (Instrumedics). We stained
sections for β-galactosidase or alkaline phosphatase activity (X-Gal and BM purple stains,
respectively, Roche), and/or with hematoxylin or eosin counter-stains. For
immunofluorescence, we post-fixed sections in cold methanol to disrupt GFP fluorescence and
incubated them with polyclonal antibodies specific for phosphorylated Smad1, Smad5 and
Smad8 (1:100, Cell Signaling) or Runx2 (M-70, 1:200, Santa Cruz Biotechnology), followed
by Alexa Fluor 488–labeled goat Fab specific for rabbit IgG (Invitrogen).
Id1 and plasminogen activator inhibitor-1 promoter luciferase reporter assays
We transiently transfected mouse PASMCs grown to 50% confluence in six-well plates with
0.3 μg Id1 promoter luciferase reporter construct (BRE-Luc30, kindly provided by P. ten Dijke)
in combination with 0.6 μg of plasmid expressing constitutively active forms of BMP type I
receptors (caALK2, caALK3 or caALK631, kindly provided by K. Miyazono), using Fugene6
(Roche). To assess activin and TGF-β type I receptor function, we transiently transfected
PASMCs with 0.3 μg PAI1 (plasminogen activator inhibitor-1) promoter luciferase reporter
construct (CAGA-Luc32, provided by P. ten Dijke) in combination with 0.6 μg of plasmid
expressing constitutively active forms of type I receptors (caALK4, caALK5 and
caALK733, provided by K. Miyazono). For both reporter plasmids, we used 0.2 μg of pRL-
TK Renilla luciferase (Promega) to control for transfection efficiency. We incubated PASMCs
with LDN-193189 (2 nM–32 μM) or vehicle starting 1 h after transfection. We harvested cell
extracts and quantified relative promoter activity by the ratio of firefly to Renilla luciferase
activity with the dual luciferase assay kit (Promega).
Range of motion analyses
To quantify impaired mobility via passive range of motion, we anesthetized transgenic and
control mice and assessed them for the ability to passively dorsiflex the left ankle joint. Scores
were assessed by two independent observers blinded to genotype and treatment. The observers
scored the minimum angle formed by the ankle and the tibia with passive dorsiflexion under
light manual pressure as follows: 0, normal flexion with a minimal angle of < 20°; 1, mildly
impaired flexion with a minimal angle of ≥ 20° but < 90°; 2, moderately impaired flexion with
a minimal angle of ≥ 90° but < 135°; and 3, severely impaired flexion with a minimal angle of
≥ 135° (depicted in Fig. 3f).
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Statistical analyses
We measured the statistical significance of compared measurements with the Student’s two-
tailed t-test.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Mouse model of FOP. (a) Staining of muscle sections from Ad.Cre-injected conditional
caALK2–expressing (ALKQ207D) mice. The injection done at P7 induced recombination in
myocytes of the left (L) gastrocnemius and soleus muscles at P11, as evidenced by loss of
nuclear β-galactosidase (β-gal) staining and gain of GFP expression. Squares indicate areas of
low magnification examined at higher magnification to the right. H&E staining reveals
mononuclear cell infiltrates and myocyte edema in tissues undergoing recombination, but not
in uninjected right (R) hindlimb muscles. (b) Left hindlimb postural abnormalities were
observed grossly (left) at P30 in the Ad.Cre-injected left hindlimbs of conditional caALK2
mice, but not in Ad.Cre-injected wild-type mice. The X-ray image (right) shows Ad.Cre-
induced ectopic calcifications involving the left gastrocnemius, soleus and hamstring muscles
of conditional caALK2 mice at P30. (c) Three-dimensional reconstructed images from μCT
cross-sections of an Ad.Cre-injected, conditional caALK2–expressing mouse on P30 showing
intramuscular ectopic bone within the left gastrocnemius, soleus, tibialis and hamstring
muscles (rendered in light gray) fusing with the pelvis and proximal femur.
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Figure 2.
Effect of LDN-193189 on BMP signaling and function. (a) Structures of dorsomorphin and
LDN-193189. (b) Quantitative immunoblotting of PASMCs showing differential effects of
dorsomorphin or LDN-193189 on BMP4–induced (10 ng ml−1) phosphorylation of Smad1,
Smad5 and Smad8 (p-Smad1/5/8), with IC50 values of ~400 nM and ~5 nM, respectively. (c)
Immunoblot of PASMCs treated with LDN-193189 showing differential inhibition of BMP4
(10 ng ml−1) or TGF-β (0.5 ng ml−1) signaling (IC50 ~ 5 nM and ≥ 1 μM, respectively). (d)
Id1 promoter activity induced by transient transfection of COS cells with ALK2R206H or
ALK2Q207D. Id1 promoter activity (BRE-Luc) was increased by 250- to 300-fold over control
plasmid (pcDNA, n = 3 measurements, mean ± s.d., NS, no significant difference). (e) Impact
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of LDN-193189 on the transcriptional activities of caALK2R206H and caALK2Q207D mutants,
expressed as percentage of full Id1 promoter activity (n = 3 measurements, mean ± s.d., *P <
0.05 versus untreated). (f) Impact of LDN-193189 (100 nM) on BMP4-induced (10 ng ml−1)
osteoblast differentiation of C2C12 cells at various intervals before and after BMP4 treatment
(n = 6 measurements, mean ± s.d., *P < 0.01 versus BMP4 treatment alone) and on cell viability
(bottom panel). (g) Top, immunoblot for p-Smad1/5/8 and total Smad1 in PASMCs expressing
the conditional caALK2Q207D transgene after infection with Ad.Cre or Ad.GFP showing the
impact of pretreatment with LDN-193189 (100 nM). Bottom, immunoblot for phosphorylated
Smad1/5/8 and total Smad1 in Ad.GFP- or Ad.Cre-infected PASMCs treated with BMP4 at
varying concentrations.
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Figure 3.
Impact of LDN-193189 on ectopic ossification in vivo. (a) Conditional caALK2–expressing
mice receiving vehicle after Ad.Cre injection on P7 developed radiographic disease at P13,
progressing to fusion of left hindlimb joints by P30–P60, whereas treatment with LDN-193189
diminished ectopic bone formation and preserved joint spaces over the same interval without
inducing fractures, osteopenia or skeletal abnormalities (n = 3–5 mice per treatment group;
data are representative of six independent experiments). (b,c) Alizarin red and Alcian blue
staining of mice at P15 showing ectopic calcifications encasing the left tibia and fibula in
vehicle-treated conditional caALK2–expressing mice, but not in LDN-193189–treated mice.
Higher magnification images are shown in c. Ectopic bone or cartilage are absent in the wild-
type hindlimb. A-P, anterior-posterior; LAT, lateral; P-A, posterior-anterior. (d) μCT imaging
showing attenuated ectopic calcification in LDN-193189–treated mice as compared to vehicle-
treated mice at P15 and P30. (e) Fixed extension of left hip, knee and ankle joints, as evident
in anesthetized and flaccid Ad.Cre-injected conditional caALK2–mutant mice at P30. The
extension is attenuated in LDN-193189-treated mice. (f) Passive range of motion impairment
score, as assessed by the minimum angle formed by the ankle and tibia with passive
dorsoflexion. (g) Impact of vehicle and LDN-193189 treatment upon passive range of motion
impairment in Ad.Cre-injected conditional caALK2–mutant mice at P15 and P30 (n as
indicated, bars represent mean, *P < 0.001).
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Figure 4.
Impact of pharmacologic inhibition of BMP signaling and inflammation in the mouse FOP
model. (a) Immunofluorescence showing enhanced nuclear p-Smad1/5/8 and expression of
Runx2 in a number of recombined (β-gal–negative) myocytes from left (L) hindlimb muscles
of Ad.Cre-injected, conditional caALK2–mutant mice at P11 (with DAPI counterstain in blue,
right). Both are diminished in LDN-193189–treated mice. Uninjected right(R)-hindlimbs are
shown as controls. (b) Histological evidence of intramuscular endochondral bone, as shown
by alkaline phosphatase staining (AlkPhos) of osteoblasts, chondrocytes, matrix and marrow
cells in recombined tissues of vehicle-treated, Ad.Cre-injected, caALK2-transgenic mice at
P30. The staining is diminished and absent in LDN-193189–treated and uninfected mice,
respectively (higher magnification, right panels). (c) High-frequency recombination evidenced
by loss of β-gal staining in muscle, vascular and connective tissues of tamoxifen-treated,
CAGGS-CreER:CAG-Z-EGFP-caALK2 mice but not single-transgenic CAG-Z-EGFP-
caALK2 mice at P30. (d) Plain radiographs of tamoxifen-treated double- and single-transgenic
mice at P60 show absence of ectopic calcification. (e) Alizarin red and Alcian blue staining
revealing ectopic calcification in tamoxifen-treated, Ad.GFP-injected double-transgenic but
not single-transgenic mice at P14. (f) Impact of dexamethasone treatment (10 mg kg−1 daily)
upon radiographic ossifications in Ad.Cre-injected, conditional caALK2–expressing mice at
P15 and P30, as compared to vehicle treatment. (g) Impact of dexamethasone treatment upon
impairment of passive range of motion (ankle flexion) in Ad.Cre-injected, conditional
caALK2–expressing mice at P15 and P30 (data are representative of three independent
experiments, n as indicated; values are mean ± s.d., *P < 0.05).
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